PROBLEM TO BE SOLVED: To provide a high dose formulation improved in leachability, tablet hardness, and pestle adhesion etc. of a drug, as for a pharmaceutical composition that contains a minodronic acid useful as a therapeutic agent for osteoporosis or a pharmaceutically acceptable salt or hydrate thereof.SOLUTION: The pharmaceutical composition contains the minodronic acid or the pharmaceutically acceptable salt or hydrate thereof, and a drug dissolution rate in 15 minutes after an elution test begins is 80% or more.